Didier Scherrer

710 citations

32 papers · 533 indexed · h-index 14

Impact in

Virology top 5%
- HIV Research and Treatment
Genetics
- Inflammatory Bowel Disease
- Coagulation, Bradykinin, Polyphosphates, and Angioedema

Papers in

Virology 7
- HIV Research and Treatment 7
Genetics 6
- Inflammatory Bowel Disease 6
- Coagulation, Bradykinin, Polyphosphates, and Angioedema 6

Co-authors: Jamal Tazi Yves Landry Aude Garcel Hartmut J. Ehrlich Fabien Schmidlin Laurent Daeffler Paul Gineste Claude Bertrand
Journals: Journal of Crohn s and Colitis (4 papers)Scientific Reports (2 papers)Annals of the Rheumatic Diseases (2 papers)Antimicrobial Agents and Chemotherapy (2 papers)Molecular Cancer Therapeutics (1 paper)
Partner nations: France United States Belgium

In The Last Decade

Didier Scherrer

30 papers receiving 521 citations

Peers

Countries citing papers authored by Didier Scherrer

Since Specialization

Citations

This map shows the geographic impact of Didier Scherrer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Didier Scherrer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Didier Scherrer more than expected).

Fields of papers citing papers by Didier Scherrer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Didier Scherrer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Didier Scherrer. The network helps show where Didier Scherrer may publish in the future.

Co-authors

The 25 scholars most cited alongside Didier Scherrer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Didier Scherrer Line = papers co-authored together Didier Scherrer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study Journal of Crohn s and Colitis ·Séverine Vermeire, Josianne Nitcheu, Paul Gineste, A Pidek, Dieter Hermann, Didier Scherrer, Laurent Peyrin-Biroulet, Parambir S. Dulai, Silvio Danese, Marla C. Dubinsky, Herbert Tilg, Britta Siegmund, Tadakazu Hisamatsu, 一至藤井, Hemal H. Parekh, Lorenzo Ortiz Fernández	2025	1
2	P025 Obefazimod and its active metabolites ABX-464-N-Glu act by stabilizing protein-protein interaction among key RNA biogenesis partners, CBC and ARS2 Journal of Crohn s and Colitis ·Patrick Bron, Katherine Martin, Nayla Nahas, Didier Scherrer, Jamal Tazi	2024	1
3	S1097 Correlation of miR-124 Upregulation and PK Parameters in Blood of Patients With Moderate-to-Severe Ulcerative Colitis Receiving Obefazimod for 16 Weeks The American Journal of Gastroenterology ·Dieter Hermann, A Pidek, Paul Gineste, Didier Scherrer, Josianne Nitcheu, Sheldon Sloan, Hartmut J. Ehrlich, Bruce E. Sands, Séverine Vermeire	2023	1
4	Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy The Journal of Infectious Diseases ·نديم روحانا, María C. Puertas, Sara Morón‐López, Ross Cranston, Víctor Urrea, Judith Dalmau, María Salgado, Cristina Gálvez, Itziar Erkizia, Ian McGowan, Didier Scherrer, Boris Revollo, Guillem Sirera, José Ramón Santos, Bonaventura Clotet, Roger Paredes, Javier Martínez‐Picado	2023	4
5	P001 Obefazimod upregulates miR-124 and downregulates the expression of some cytokines in blood and rectal biopsies of patients with moderate-to-severe ulcerative colitis. Journal of Crohn s and Colitis ·Dieter Hermann, Paul Gineste, Didier Scherrer, Josianne Nitcheu, Hartmut J. Ehrlich, B E Sands, Séverine Vermeire	2023	2
6	Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models Molecular Cancer Therapeutics ·Didier Scherrer, 昭子下村, Luc Teyton, Tillman Pearce, Josianne Nitcheu, O. and Dubey, Dieter Hermann, Hartmut J. Ehrlich	2022	1
7	ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension The Lancet. Gastroenterology & hepatology ·Séverine Vermeire, Bruce E. Sands, Herbert Tilg, Zsolt Tulassay, Radosław Kempiński, Silvio Danese, Ivan Bunganič, Josianne Nitcheu, Dieter Hermann, Didier Scherrer, Miguel Gutiérrez Saxe, Hartmut J. Ehrlich, Cruz Acosta, Paul Gineste, William J. Sandborn	2022	41
8	Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing Scientific Reports ·Lois L. Marcello, Cornelia Stelzer, Aude Garcel, Filipe Gouveia Cavalcante, Laure Lapasset, O. Brutti, Marzia Olivieri, Evgeny Aleksandrovich Malyavko, Emeric Dubois, Didier Scherrer, Filiz ÖNAL, Jamal Tazi	2019	49
9	RNA sequencing analysis of activated macrophages treated with the anti-HIV ABX464 in intestinal inflammation Scientific Data ·Cornelia Stelzer, 裴倩敏, Laura Papon, Conception Paul, Aude Garcel, Filipe Gouveia Cavalcante, Didier Scherrer, Hartmut J. Ehrlich, Michael Hahne, Jamal Tazi	2017	4
10	Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects Journal of Antimicrobial Chemotherapy ·Didier Scherrer, Roman Rouzier, Perry Barrett, Cruz Acosta, Paul Gineste, Robert L. Murphy, Jamal Tazi, Hartmut J. Ehrlich	2016	14
11	Pharmacological modulation of LMNA SRSF1-dependent splicing abrogates diet-induced obesity in mice International Journal of Obesity ·Dieter Hermann, Anne Lene Gerdes, Lucia F Lopez, Yacine Barèche, Laure Lapasset, Carine Chavey, Wei‐Chang Wu, Florence Mahuteau‐Betzer, Tatyana Shirokova, S. Inkelas, Isabel C. López‐Mejía, Guillaume E. Béranger, François Casas, Ez‐Zoubir Amri, Bernard Pau, Didier Scherrer, Jamal Tazi	2016	7
12	Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis Retrovirology ·Filipe Gouveia Cavalcante, Renier Myburgh, Aude Garcel, Lois L. Marcello, Laure Lapasset, 임헌규, Florence Mahuteau‐Betzer, Tatyana Shirokova, S. Inkelas, مريم عواد الزيادات, Eugénia Basyuk, Martial Sevéno, Julian P. Venables, Bernard Pau, Édouard Bertrand, Mark A. Wainberg, Roberto F. Speck, Didier Scherrer, Jamal Tazi	2015	73
13	RabGEF1 is a negative regulator of mast cell activation and skin inflammation Nature Immunology ·See‐Ying Tam, Mindy Tsai, John N. Snouwaert, Janet Kalesnikoff, Didier Scherrer, Susumu Nakae, Devavani Chatterjea, Donna M. Bouley, Stephen J. Galli	2004	54
14	Glucocorticoids increase bradykinin B2 receptor gene transcription in cultured guinea-pig tracheal smooth muscle cells Naunyn-Schmiedeberg s Archives of Pharmacology ·Didier Scherrer, Fabien Schmidlin, El‐Bdaoui Haddad, Olivier Kassel, Yves Landry, J.-P. Gies	1999	10
15	Glucocorticoids inhibit the bradykinin B2 receptor increase induced by interleukin-1β in human bronchial smooth muscle cells European Journal of Pharmacology ·Fabien Schmidlin, Didier Scherrer, Yves Landry, Nurfadilla Yustina Putri	1998	13
16	Effect of WIN 64338, a B₂bradykinin receptor antagonist on guinea‐pig tracheal smooth muscle cells in culture Fundamental and Clinical Pharmacology ·Didier Scherrer, Fabien Schmidlin, 张才乔, V Colanović, Yves Landry, ndranil Mitra	1998	3
17	Glucocorticoid modulation of muscarinic and β‐adrenergic receptors in guinea pig lung Fundamental and Clinical Pharmacology ·Didier Scherrer, 张才乔, Yves Landry, ndranil Mitra	1997	12
18	M₂-Muscarinic Receptors: How Does Ligand Binding Affinity Relate to Intrinsic Activity? Journal of Receptors and Signal Transduction ·Ahmad Ali Widodo, Laurent Daeffler, Didier Scherrer, Marc Mousli, Yves Landry, Nidhin S	1996	7
19	Effects of WIN 64338, a nonpeptide bradykinin B₂ receptor antagonist, on guinea‐pig trachea British Journal of Pharmacology ·Didier Scherrer, Laurent Daeffler, Alexandre Trifilieff, Jean‐Pierre Gies	1995	10
20	Association of guinea pig lung bombesin receptors with pertussis toxin-sensitive guanine nucleotide binding proteins European Journal of Pharmacology Molecular Pharmacology ·张才乔, Alexandre Trifilieff, Didier Scherrer, J. Winfield Fretz	1994	2

About Didier Scherrer

Didier Scherrer is a scholar working on Virology, Genetics, Immunology, Infectious Diseases and Hepatology, having authored 32 papers that have together received 533 indexed citations. Recurring topics across this work include HIV Research and Treatment (7 papers), Inflammatory Bowel Disease (6 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers), HIV/AIDS drug development and treatment (6 papers), MicroRNA in disease regulation (4 papers), Immune Cell Function and Interaction (4 papers), Receptor Mechanisms and Signaling (4 papers) and Hepatitis C virus research (3 papers). The work is most often cited by research in Virology (90 citations), Genetics (78 citations), Immunology (124 citations), Cancer Research (81 citations) and Infectious Diseases (92 citations). Didier Scherrer has collaborated with scholars based in France, United States and Belgium. Frequent co-authors include Jamal Tazi, Yves Landry, Aude Garcel, Hartmut J. Ehrlich, Fabien Schmidlin, Laurent Daeffler, Paul Gineste, Claude Bertrand, Laure Lapasset and J.-P. Gies. Their work appears in journals such as Journal of Crohn s and Colitis, Scientific Reports, Annals of the Rheumatic Diseases, Antimicrobial Agents and Chemotherapy and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact